专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2004037784A2 PYRROLIDONES WITH ANTI-HIV ACTIVITY 审中-公开
标题翻译：具有抗HIV活性的吡咯烷酮
公开(公告)号：WO2004037784A2
公开(公告)日：2004-05-06
申请号：PCT/US2003/033560
申请日：2003-10-21
申请人： IRM LLC , WU, Baogen , HE, Yun , NGYUEN, Truc , KUHEN, Kelli, L. , ELLIS, David, Archer , JIANG, Tao
发明人： WU, Baogen , HE, Yun , NGYUEN, Truc , KUHEN, Kelli, L. , ELLIS, David, Archer , JIANG, Tao
IPC分类号： C07D
CPC分类号： C07D207/26 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12
摘要： The present invention relates to inhibition of viruses, e.g. , HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
摘要翻译：本发明涉及使用吡咯烷酮和涉及吡咯烷酮的化合物来抑制HIV病毒，例如HIV。本发明进一步涉及鉴定和使用试剂的方法，所述试剂包括抑制细胞中HIV的小分子化学组合物; 以及涉及艾滋病毒感染和艾滋病等相关疾病的预防和治疗方法。

32. 发明申请

WO2003045980A3 GLYCOPEPTIDE REMODELING USING AMIDASES 审中-公开
公开(公告)号：WO2003045980A3
公开(公告)日：2003-06-05
申请号：PCT/US2002/038440
申请日：2002-11-27
申请人： NEOSE TECHNOLOGIES, INC. , DEFREES, Shawn
发明人： DEFREES, Shawn
IPC分类号： C12P21/06
摘要： This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a homogeneous glycosylation pattern.

33. 发明申请

WO2003037900A2 PYRAZOLOPYRIMIDINES 审中-公开
标题翻译：吡唑并嘧啶
公开(公告)号：WO2003037900A2
公开(公告)日：2003-05-08
申请号：PCT/US2002/035171
申请日：2002-11-01
申请人： ICAGEN, INC. , ATKINSON, Robert, Nelson , GROSS, Michael, Francis , VAN RHEE, Michiel, Albert
发明人： ATKINSON, Robert, Nelson , GROSS, Michael, Francis , VAN RHEE, Michiel, Albert
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , A61K31/519
摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazolopyrimidines, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.
摘要翻译：提供了通过抑制钠离子通过电压依赖钠通道来治疗疾病的化合物，组合物和方法。更具体地，本发明提供了可用于治疗中枢或周围神经系统疾病，特别是疼痛和慢性疼痛的吡唑并嘧啶类，组合物和方法，其通过阻断与所述病症的发作或复发有关的钠通道。本发明的化合物，组合物和方法特别用于通过包含PN3亚基的通道抑制离子通量来治疗神经性或炎性疼痛。

34. 发明申请

WO2002074388A1 BISARYLAMINES AS POTASSIUM CHANNEL OPENERS 审中-公开
标题翻译：双磺胺作为钾通道开放剂
公开(公告)号：WO2002074388A1
公开(公告)日：2002-09-26
申请号：PCT/US2002/007744
申请日：2002-03-15
申请人： ICAGEN, INC. , MCNAUGHTON-SMITH, Grant, A. , AMATO, George, S.
发明人： MCNAUGHTON-SMITH, Grant, A. , AMATO, George, S.
IPC分类号： A61P25/00
CPC分类号： C07D401/12 , A61K31/4439 , C07D413/12 , C07D413/14
摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides bisarylamines, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by opening potassium channels associated with the onset or recurrence of the indicated conditions.
摘要翻译：提供了通过电压依赖钾通道调节钾离子通量可用于治疗疾病的化合物，组合物和方法。更具体地，本发明提供了可用于治疗中枢性或周围神经系统疾病（例如偏头痛，共济失调，帕金森病，双相情感障碍，三叉神经痛，痉挛状态，情绪障碍，脑肿瘤，精神病性障碍）的二芳基胺，组合物和方法，迷走神经，癫痫，癫痫，听力和视力丧失，阿尔茨海默病，年龄相关的记忆丧失，学习缺陷，焦虑和运动神经元疾病）和作为神经保护剂（例如，以预防中风等）指示条件的发生或复发。

35. 发明申请

WO2022235830A1 LOW X-RAY ATTENUATION CHANGE HARD SHELLED ORAL CONTRAST MATERIAL 审中-公开
公开(公告)号：WO2022235830A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/027712
申请日：2022-05-04
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： YEH, Benjamin, M. , SUN, Yuxin
IPC分类号： A61B6/00 , A61K49/04 , G09B23/28
摘要： The present invention provides a hollow borosilicate microparticle contrast media for use in CT imaging with shell material containing less than 8% oxides of non-silicon elements with atomic number greater than 10. In an exemplary embodiment, the invention provides an enteric contrast medium formulation which provides CT numbers distinct from those of water, soft tissue, and fat. An exemplary formulation comprises, (a) an enteric contrast medium comprising a hollow borosilicate microparticle suspended in water. In various embodiments, the hollow borosilicate microparticle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. The invention also provides methods for imaging of the abdomen and pelvis by CT imaging contemporaneously with the delivery of the hollow borosilicate microparticle contrast material into the bowel lumen.

36. 发明申请

WO2022099223A2 PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION 审中-公开
公开(公告)号：WO2022099223A2
公开(公告)日：2022-05-12
申请号：PCT/US2021/064437
申请日：2021-12-20
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , ANWAR, Hassouna Hany , YU, Joshua Elliot , ZAYDENBERG, Alexander , DER-SARKISSIAN, Ani , BADDOUR, Yasser , VINCENT, Emily , GAVIT, Patrick D.
发明人： HASSOUNA, Hany Anwar , YU, Joshua Elliot , ZAYDENBERG, Alexander , DER-SARKISSIAN, Ani , BADDOUR, Yasser , VINCENT, Emily , GAVIT, Patrick D.
IPC分类号： C07K14/75 , B01D15/26 , C07K14/755
摘要： Efficient methods for capture and removal of fibrinogen from blood plasma fractions, especially cryoprecipitate, and Fraction II+III providing high yields of blood coagulation Factor VIII are disclosed. According to this disclosure, there is provided a method of separating plasma cryoprecipitate or Fraction II+III comprising a blood coagulation factor and fibrinogen into a first fraction comprising the blood coagulation factor and a second fraction containing the fibrinogen, the method comprising: (a) contacting the plasma cryoprecipitate with solid SiO2 or Al(OH)3, thereby adsorbing the fibrinogen onto the solid SiO2 or Al(OH)3; and (b) separating the fibrinogen adsorbed onto the solid SiO2 or Al(OH)3 from the blood factor, thereby forming the first fraction and the second fraction.

37. 发明申请

WO2022051647A2 CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEIN CONSTRUCTS WITH HUMAN SERUM ALBUMIN DOMAINS 审中-公开
公开(公告)号：WO2022051647A2
公开(公告)日：2022-03-10
申请号：PCT/US2021/049109
申请日：2021-09-03
申请人： MAVERICK THERAPEUTICS, INC. , HICKLIN, Daniel J.
发明人： DUBRIDGE, Robert B. , CULP, Patricia A.
IPC分类号： C07K16/18 , C07K16/28 , C07K16/30 , A61P35/00 , C07K14/765 , C07K16/32 , C07K16/2809 , C07K16/2827 , C07K16/2863 , C07K2317/31 , C07K2317/569 , C07K2317/62 , C07K2317/622 , C07K2317/94 , C07K2319/00 , C07K2319/31 , C07K2319/50
摘要： Provided herein are Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format, which includes a human serum albumin (HSA) domain that increases its serum half-life. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, and thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

38. 发明申请

WO2021231651A8 SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS 审中-公开
公开(公告)号：WO2021231651A8
公开(公告)日：2021-11-18
申请号：PCT/US2021/032092
申请日：2021-05-12
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： SAUNDERS, Reuben , BILLESBOELLE, Christian , WALTER, Peter , MANGLIK, Aashish , SCHOOF, Michael , FAUST, Bryan , HOPPE, Nicholas
IPC分类号： A61K38/162 , A61P31/12 , C07K16/10 , C07K16/28 , C07K16/32 , A61K2039/505 , C07K2317/22 , C07K2317/24 , C07K2317/34 , C07K2317/35 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.

39. 发明申请

WO2020257539A1 SYSTEMS AND METHODS FOR FABRICATING A MICROCHANNEL VASCULAR NETWORK DEVICE AND SEEDING A MICROCHANNEL 审中-公开
公开(公告)号：WO2020257539A1
公开(公告)日：2020-12-24
申请号：PCT/US2020/038560
申请日：2020-06-18
申请人： 3D BIOLABS, LLC
发明人： VACANTI, Joseph, P. , BYAMBAA, Batzaya , COMER, Carly , HANCOCK, Matthew, James , LIEBERTHAL, Tyler , SAHAKYANTS, Tatevik , SPANN, Andrew, Paul , NEVILLE, Craig
IPC分类号： C12M3/06 , C12M1/26 , C12M1/36
摘要： A method of fabricating a microchannel device is provided. The method includes determining, based on a plurality of design criteria, a microchannel vascular network design. The microchannel vascular network design includes a first channel network, a second microchannel network based on the first channel network, and a structure for providing fluidic communication through between the first channel network and the second channel network. The method includes receiving, in electronic form, the microchannel vascular network design at a fabrication system. The fabrication system comprises a pre-polymer solution. The method includes forming, based on the microchannel vascular network design, a microchannel vascular network device of a polymer material at the fabrication system using the pre-polymer solution, thereby fabricating the microchannel vascular network device.

40. 发明申请

WO2020033904A1 METHOD AND MATERIAL TO ACQUIRE MAGNETIC RESONANCE IMAGING DATA 审中-公开
公开(公告)号：WO2020033904A1
公开(公告)日：2020-02-13
申请号：PCT/US2019/046022
申请日：2019-08-09
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： YEH, Benjamin, M.
IPC分类号： A61K49/06 , A61K49/04 , A61K49/18 , A61K49/22
摘要： Provided are MR images of a subject gastrointestinal tract structure in which the lumen of the structure is usefully darkened on both T1-weighted and T2-weighted images when the structure is imaged following administration to the subject of an enteric contrast agent formulation with particles containing encapsulated gas or partial vacuum. The present invention provides an encapsulated gas or partial vacuum particle contrast medium of use in acquiring such MR images. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式